News
The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...
Eli Lilly raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, ...
In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...
Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...
In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...
Earnings, adjusted for one-time gains and costs, came to $6.31 per share. The results surpassed Wall Street expectations. The ...
As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...
Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...
Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove ...
1hon MSN
These Stocks Are Moving the Most Today: Fortinet, AppLovin, Eli Lilly, Airbnb, Duolingo, and More
Fortinet, AppLovin, Airbnb, Duolingo and more stock were making big moves Thursday after the companies reported quarterly ...
The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year or so.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results